Despite intense recent interest, the suppressive mechanisms of regulatory CD251CD4 T cells remain poorly understood. One deficiency in the field is the lack of in vivo models where the effects of regulatory CD251CD4 T cells on antigen-specific responder T cells can be measured quantitatively.
Introduction
Regulatory CD25+CD4 T cells are well recognized to play an essential role in the maintenance of immunological tolerance, but their suppressive mechanisms remain unclear (1) (2) (3) (4) . There is broad agreement that their ability to suppress in vitro is dependent on direct contact with the responder T cells and independent of any soluble factors or inhibitory effects on the function of antigen-presenting cells (APCs) (4) (5) (6) . However, different mechanisms may play a dominant role in vivo. In fact, distinct mechanisms may operate in lymphopenic and nonlymphopenic hosts, as well as within secondary lymphoid tissues and peripheral tissues. Mechanistic studies of T cell responses in vivo can be greatly enhanced by the ability to track the fate of antigen-specific responder T cells. The goal of this study was to establish a relatively simple in vivo model system that can be used to quantify the effects of regulatory CD25+CD4 T cells on antigen-specific T cell responses in normocytic animals.
Regulatory CD25+CD4 T cells are present in greatly decreased numbers in CD28ÿ/ÿ mice (7, 8) . Thus, we compared responses of adoptively transferred antigen-specific naive TCR transgenic (Tg) CD4 T cells in wild-type and CD28ÿ/ÿ recipients. We found that the TCR Tg CD4 T cell responders proliferate to a significantly greater extent in CD28-deficient hosts following antigenic challenge, and re-constitution of CD28-deficient hosts with wild-type CD25+CD4 T cells inhibits proliferative responses of antigen-specific CD4 T cells in a dose-dependent manner. Furthermore, enhanced cell cycle progression of antigen-specific CD4 T cells in CD28-deficient hosts correlates with their increased differentiation into IFN-c and IL-4-producing effector cells and a defect in tolerance induction. These results compliment previously published reports of in vivo suppression by antigen-specific CD25+CD4 T cells (9) (10) (11) and introduce some differences which may lead to eventual greater mechanistic insight.
Methods

Mice
DO11
.10 TCR Tg RAG-2ÿ/ÿ mice extensively backcrossed onto the BALB/c background were used as donors of CD4 T cells. The mice were bred and maintained as previously described (12) . In the majority of the experiments, normal female BALB/c mice purchased from the National Cancer Institute (Frederick, MD, USA) was used as recipients at 6-10 weeks of age. CD28ÿ/ÿ mice on the BALB/c background were originally purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and bred subsequently at our facility. Thy1.1 congenic BALB/c mice were a generous gift of Laurence Turka (University of Pennsylvania, Philadelphia, PA, USA). HA TCR Tg RAG-2ÿ/ÿ mice were used as intermediate hosts to generate effector DO11.10 T cells (28) . All mice were maintained in a specific pathogen-free facility in microisolator cages with filtered air according to the National Institutes of Health guidelines. All experiments were approved by the Institutional Animal Care and Use Committee at the University of Minnesota.
Adoptive transfer and immunizations
Unless otherwise specified, responder donor T cells from the secondary lymphoid tissues (axillary, brachial, cervical, inguinal, mesenteric lymph nodes, and spleen) were labeled with 5,6-carboxyfluorescein diacetate succinimyl ester (CFSE; Molecular Probes, Eugene, OR, USA) using the technique previously described (13) and injected into the tail vein at 2.5-5 3 10 6 cells per specified recipient mouse (14) . Some of the CD28ÿ/ÿ recipient mice were re-constituted with varying numbers of wild-type CD25+CD4 T cells, which were prepared in >95% purity using positive selection using streptavidinlabeled magnetic microbeads and columns (Miltenyi Biotech, Inc., Auburn, CA, USA) following staining with biotinylated anti-CD25 mAb, PC61.
Various immunization protocols were used. Some mice were injected subcutaneously with the ovalbumin protein emulsified in CFA (Sigma-Aldrich, St. Louis, MO, USA) into three sites-tail base and bilaterally in the upper dorsum, 50 ll per injection (1 mg of protein/per milliliter of emulsion). Some mice were immunized with varying amounts of the ovalbumin peptide (OVA) 323-339 (25-250 lg per mouse) intravenously alone or with soluble adjuvants, which included LPS (25 lg per mouse) and cholera toxin (0.5 lg per mouse). Some mice were immunized with varying amounts of LPS-free ovalbumin protein alone or with soluble adjuvants mentioned. In most of the experiments, we used 500 lg of the ovalbumin protein.
Chicken ovalbumin purchased from Sigma-Aldrich was found to have significant contamination with LPS. Therefore, LPS was removed from the commercial protein by phase separation using a protocol previously described (15) . Every batch of the ovalbumin protein was tested for the ability to upregulate B7-2 expression on splenic CD11cCD8a + and CD11cCD8a ÿ cells in vivo 9 h following intravenous injection of 5 mg of ovalbumin, time of peak B7 up-regulation by LPS (16) . 'Clean' protein did not have this activity (2 mg per mouse injected intravenously), while it was easily seen with the unpurified commercial ovalbumin.
Secondary adoptive transfer
Effector DO11.10 T cells capable of efficient homing into secondary lymphoid tissues and producing IFN-c and IL-4 were prepared using intermediate HA RAGÿ/ÿ hosts. Naive DO11.10 RAGÿ/ÿ T cells were adoptively transferred into HA RAGÿ/ÿ mice that received 500 lg of the LPS-free ovalbumin protein and 250 lg of anti-CTLA-4 mAb, 4F10. Seven days later, the T cells were purified by negative selection against I-Ad, CD11b and DX5 using biotinylated antibodies and streptavidin-coated magnetic microbeads (Miltenyi Biotech, Inc.), labeled with CFSE, and transferred into BALB/c or CD28ÿ/ÿ recipients.
Flow cytometry
Single-cell suspensions were prepared separately from the lymph nodes (axillary, brachial and inguinal) and spleens by mechanical disruption. DO11.10 T cells were identified using fluorochrome-conjugated antibodies, KJ1-26 and CD4 (Caltag [San Francisco, CA, USA], BD Pharmingen [San Diego, CA, USA], eBioscience [San Diego, CA, USA]). DTA-1 hybridoma was generously provided by Shimon Sakaguchi (Kyoto University, Japan). Intracellular staining for cytokines was done as previously described following direct in vivo stimulation with the peptide (12, 17, 18) . Briefly, mice received an intravenous injection of indicated dose of the OVA 323-339 and sacrificed 1 h later. Immediately after that, lymphoid tissues were disrupted into a single-cell suspension and fixed in 2% formaldehyde for 20 min. The cells were then permeabilized with a saponin-containing buffer and stained with PE-conjugated antibodies against IL-2, IL-4, IFN-c or isotype controls (BD Pharmingen and eBioscience).
Results
Regulatory CD25+CD4 T cells inhibit proliferation and clonal expansion of naive CD4 T cells
The DO11.10 adoptive transfer system where responses of a limiting number of TCR Tg Tcells can be physically tracked is a well-established method to measure antigen-specific T cell responses in vivo (14, 19) . We used this system to compare the response of naive antigen-specific CD4 T cells in wild-type and CD28ÿ/ÿ recipients. Both thymic development and peripheral homeostasis of regulatory CD25+CD4 T cells are greatly dependent on B7/CD28 signals (8); thus, CD28-deficient and B7-deficient mice have a significant reduction in the numbers of these cells (7, 10; Fig. 1 ). Indeed, we found that clonal expansion of DO11.10 T cells is significantly greater in CD28-deficient recipients following intravenous injection of the OVA and LPS ( Fig. 2A) . Pre-transfer of wild-type CD25+CD4 T cells into the CD28-deficient recipients inhibited this increase in a dose-dependent manner (Fig. 2B ). Augmented expansion of DO11.10 T cells was also seen following stimulation with the OVA or protein alone or in combination with adjuvants such as LPS, CFA and anti-CTLA-4 mAb (4F10) (data not shown). Pre-transfer of CD25+CD4 T cells, but not CD25ÿCD4 T cells, from wild-type mice was inhibitory under all conditions (data not shown). In most of the experiments described below, we used 5-10 3 10 6 CD25+CD4 T cells to achieve partial re-constitution of the CD28ÿ/ÿ mice. This transfer achieves a level of~2% among the spleen CD4 T cells (Fig. 2B ), compared with 5-10% CD25+ T cells within the CD4 T cell population in the wild-type mice. The relatively poor 'parking efficiency' of transferred CD25+CD4 T cells compared with CD25ÿCD4 T cells has been noted previously and proposed to be at least in part due to limited responsiveness of these cells to chemokine-induced migration into the secondary lymphoid tissues (20) . Alternatively, it may merely be a consequence of the host partially clearing cells coated with anti-CD25 antibody at the time of the transfer.
Clonal expansion measured in the secondary lymphoid tissues is a function of clonal proliferation, death and migration into tissues. In order to gain better understanding of the enhanced clonal expansion in the CD28-deficient hosts, we calculated how many times an average DO11.10 T cell divided in the course of the primary immune response by measuring the CFSE content of the DO11.10 population. Clearly, responder T cells divided more times in the CD28ÿ/ÿ recipients ( Fig. 2A) . As expected, DO11.10 T cells that divided the most were preferentially lost from the secondary lymphoid tissues of the BALB/c recipients after reaching peak expansion on day 3 after antigen exposure. This loss is in part attributable to cell death but may also be partially due to preferential migration of high dividers into non-lymphoid tissues (21) (22) (23) . Interestingly, the disappearance of highly divided CD4 responders from secondary lymphoid tissues was blunted in the CD28ÿ/ÿ recipients. Therefore, the presence of CD25+CD4 T cells affects both the expansion and contraction phases of the primary immune response.
CD28-deficient and wild-type mice provide comparable environments for antigen presentation at the initial stages of T cell activation One explanation for greater T cell responses in CD28-deficient recipients is relative hyper-activation of the innate immune system, especially the APCs. It is likely that the most important APCs that initiate the T cell response are the dendritic cells (DCs) (17, (24) (25) (26) (27) . We found no differences in the absolute numbers or relative proportions of myeloid, lymphoid and plasmacytoid DCs or levels of MHC Class II or B7 expression by any of the DC subsets in CD28-deficient and wild-type BALB/c mice (data not shown). In addition, production of IL-2 by the DO11.10 T cells in vivo following stimulation by intravenous OVA did not differ between CD28-deficient and normal BALB/c recipients along a range of kinetic time points and antigen doses (Fig. 3) . Thus, the responding T cells did not appear to sense any enhanced antigen-presenting ability of DCs in CD28-deficient animals. Furthermore, no differences in basic phenotypic characteristics of DCs and functional responses of DO11.10 were seen in RAGÿ/ÿ recipient mice, which have an absolute deficiency in regulatory T cells (28) . These results suggest that regulatory CD25+CD4 T cells do not impair the encounter of responder T cells with DCs or the early T cell activation events that follow.
CD25+CD4 T cells inhibit differentiation of naive antigenspecific CD4 T cells into T h 1 and T h 2 phenotypes
The next question we wished to address is how CD25+CD4 T cells affect T cell differentiation in the course of the primary immune response. We measured cytokine production by DO11.10 T cells directly in vivo following a bolus intravenous injection of the OVA as a re-challenge. Significant proportion of DO11.10 T cells in the lymph nodes of CD28ÿ/ÿ animals primed with ovalbumin/CFA produced IL-4, but little IFN-c, while no IL-4 or IFN-c production by DO11.10 Tcells was noted in the lymph nodes of wild-type BALB/c recipient mice (Fig. 4) . In contrast, IFN-c was produced by a fraction of DO11.10 T cells in the spleens of animals immunized with OVA and LPS. This fraction is increased~2-fold in CD28-deficient recipients. However, production of both IL-4 and IFN-c was decreased in CD28-deficient animals that were partially re-constituted with wild-type CD25+CD4 T cells (Fig. 4) .
One possible explanation for this result is the direct suppression of IL-4 and IFN-c production by CD25+CD4 T cells during the in vivo re-stimulation assay. We considered this possibility unlikely since CD25+CD4 T cells could not suppress production of IL-2 by naive CD4 T cells. Nevertheless, the possibility was tested. We measured cytokine production of primed DO11.10 T cells in vitro with phorbol myristate acetate and ionomycin following depletion of all CD25+CD4 T cells. Purified primed DO11.10 T cells from CD28-deficient recipients produced more IL-4 and IFN-c than primed DO11.10 T cells from BALB/c mice and CD28-deficient mice re-constituted with CD25+CD4 T cells (data not shown). In addition, we tested the ability of effector DO11.10 T cells generated in HA RAGÿ/ÿ mice and re-transferred into BALB/c and CD28ÿ/ÿ secondary recipients to produce IL-2, IFN-c and IL-4 following a re-challenge with the OVA. No differences were found (Fig. 5A) . However, similar to what we have noted for naive T cells, the effector DO11.10 T cells proliferated to a lesser extent in wild-type as compared with CD28ÿ/ÿ hosts following secondary antigenic challenge (Fig. 5B) . Thus, in our system, CD25+CD4 T cells could not inhibit cytokine production by naive or effector CD4 T cells, but did inhibit CD4 T cell differentiation, which correlated with inhibition of the proliferative response to antigenic stimulation.
Peripheral tolerance induction following systemic antigen administration fails in CD28ÿ/ÿ hosts Greater differentiation and functional responsiveness of CD4 T cells in the course of primary immune response have been associated with greater number of cell divisions (29) . Since CD28ÿ/ÿ hosts supported greater proliferation and differentiation by adoptively transferred antigen-specific CD4 T cells, we tested whether the two variables correlate. CFSE-labeled DO11.10 RAGÿ/ÿ T cells were adoptively transferred into wild-type and CD28ÿ/ÿ mice, which were then administered 500 lg of the LPS-free ovalbumin protein intravenously. The protocol induces a state of hyporesponsiveness in antigen-specific CD4 T cells, which can be prevented by the addition of adjuvant to the antigen during priming (12) . Eight days after initial antigen administration, we measured the numbers of DO11.10 T cells, their CFSE content and recall cytokine production in spleens and lymph nodes of the recipients following a 1-h re-challenge with the OVA. Indeed, as expected, we saw greater IL-2 production by T cells with greater cell division history and DO11.10 T cells proliferated to a greater extent in CD28ÿ/ÿ hosts and made more IL-2 (Fig. 6) . Interestingly, the most highly divided DO11.10 T cells also made a significant amount of IL-4 in CD28ÿ/ÿ animals (Fig. 6) . The enhanced proliferation and differentiation of DO11.10 T cells in CD28ÿ/ÿ hosts in response to ovalbumin protein administration was inhibited by adoptive transfer of wild-type CD25+CD4 T cells (data not shown). The result is consistent with the idea that naturally occurring CD25+CD4 T cells normally promote tolerance induction of CD4 T cells responding to cognate antigens.
Discussion
Although there are several well-established in vitro assays of suppressive functions of regulatory CD25+CD4 T cells (4) (5) (6) 30) , it is unlikely that they fully capture the suppressive mechanisms these cells employ in vivo. In fact, the ability of regulatory CD25+CD4 T cells to suppress proliferation of responder CD4 T cells in vitro is critically dependent on the suppression of IL-2 production (30), and greatest suppression is seen when IL-2 is limiting. In contrast, IL-2 is not essential for proliferation of CD4 T cells in vivo (18, 31) , and regulatory CD25+CD4 Tcells can suppress IL-2-deficient responder CD4 T cells in vivo (32) . Suppression by CD25+CD4 T cells in vitro is dependent on direct contact with the responder CD4 Tcells and is independent of any effects on APCs or production of soluble suppressive cytokines (4, 6, 30) . In contrast, regulatory CD25+CD4 T cells have been shown to suppress elements of the innate immune system in vivo, and soluble cytokines, e.g. IL-10, have been shown to play a critical role in their suppressive activity (33, 34) . In fact, it is possible that regulatory CD25+CD4 T cells employ multiple suppressive mechanisms in vivo that differ depending on the specific type of the responder cell, tissue location (e.g. secondary lymphoid tissue versus periphery) and presence or absence of lymphopenia. Thus, there is a need for robust in vivo models that can measure suppressive effects of regulatory CD4 T cells.
Here, we focused on developing a relatively simple model of suppression mediated by regulatory CD4 T cells on antigenspecific naive responder CD4 T cells in the secondary lymphoid tissues of a non-lymphopenic animal. The total numbers of T cells are comparable in wild-type and CD28ÿ/ÿ animals (35) . However, the numbers of regulatory CD25+CD4 T cells are greatly reduced in CD28ÿ/ÿ and B7ÿ/ÿ animals because of critical importance of B7 : CD28 signals for homeostasis of these cells (7, 8, 10) . We found that adoptively transferred RAGÿ/ÿ T cells were adoptively transferred into the following hosts: wild-type BALB/c, CD28ÿ/ÿ and CD28ÿ/ÿ partially re-constituted with regulatory wild-type CD25+CD4 T cells. Some of the mice were immunized with ovalbumin protein and CFA subcutaneously, while others received OVA and LPS intravenously. The histograms on the left show cytokine production by DO11.10 T cells in the draining lymph nodes 1 h after intravenous re-challenge with 250 lg of the OVA done 9 days after original priming with ovalbumin and CFA. The histograms on the right show cytokine production by DO11.10 T cells in the spleens 8 days after immunization with the OVA/LPS 1 h after OVA pulse re-challenge. The experiment is representative of five independent experiments. Cumulative data from these experiments on antigen-specific recall responses is shown in the bar graphs. Original priming conditions are indicated. The modestly increased recall production of IFN-c in the ovalbumin/LPSprimed CD28ÿ/ÿ hosts is statistically significant compared with other groups (P < 0.01).
responder CD4 T cells exhibited increased clonal expansion in CD28ÿ/ÿ recipients due to greater proliferative response and lesser degree of contraction following peak expansion. Greater proliferative response was also accompanied by greater differentiation of the antigen-specific CD4 T cells into IFN-c and IL-4 producers, while the direction and extent of differentiation was determined by the specific adjuvant used. In addition, we found lack of tolerance induction by systemic administration of antigen without adjuvant. Although we considered and tested alternative potential explanations for these results, e.g. baseline activation of the innate immune system in immunocompromised CD28ÿ/ÿ hosts, the only explanation we found support for was deficiency in regulatory CD25+CD4 T cells in CD28ÿ/ÿ hosts.
Interestingly, we found no effect of CD25+CD4 T cells on naive or effector responder T cell function on cytokine production, which takes place within hours of antigen stimulation. In addition, the differences in proliferative responses of antigen-specific CD4 T cells in the presence or absence of CD25+CD4 T cells were not discernable until day 3 and became progressively more prominent at later time points. This result is consistent with observations made by Klein and colleagues, where antigen-specific CD25+C4 T cells did not affect the initial expansion of naive T cells following stimulation with antigen/incomplete Freund's adjuvant but suppressed their eventual accumulation (9) . These results suggest that CD25+CD4 Tcells can mediate their effects after the initial Tcell activation events are completed.
It should be noted that despite considerable effort, we could not demonstrate that CD28-deficient hosts were equivalent to wild-type hosts depleted with anti-CD25 antibodies, despite a trend toward greater differentiation of DO11.10 CD4 T cells in CD25-depleted animals (data not shown). Some of the reasons for the difference are probably technical. Thus, the residual antibody depleted significant numbers of responder DO11.10 cells, which expressed CD25 following antigen activation (data not shown). Although our protocol depleted CD25+ cells with >95% efficiency, we cannot fully rule out the possibility that some residual CD25+CD4 T cells still continued to provide suppression, even though our titration studies with re-constitution of CD28ÿ/ÿ hosts would argue that relatively small residual numbers of regulatory CD25+CD4 would be ineffective. It is possible that there are CD25-regulatory T cells that are also dependent on CD28 signals for their generation and/or maintenance. Suppressive CD25ÿGITR+CD4 T cells have been reported in wild-type mice (36) . Finally, it cannot be assumed that anti-CD25 depletion exclusively targets regulatory CD25+CD4 T cells, since other cell types that may be important in the immune response toward a systemic antigen, e.g. recently described accessory cells (37) , express CD25.
Our system is similar to the one described by Lohr and colleagues (10) , where responder DO11.10 T cells were stimulated in vivo by ovalbumin-pulsed DCs in wild-type and B7-deficient hosts. However, there are some significant differences in the results. While our system showed clear correlation of greater functional T cell differentiation with greater cell cycle progression, no difference in cell cycling activity was seen in their experiments between wild-type and B7-deficients hosts (10) . One major difference is in antigen presentation. In contrast to T cell stimulation by antigen-pulsed DCs, we administered systemic antigen, which is likely taken up by a variety of APCs including DCs, recently described accessory cells (37) and B cells, all of which may participate in driving clonal expansion. It is also formally possible that there is a difference in the amount of B7 signaling following immunization with DCs in B7-sufficient and B7-deficient hosts if antigennon-bearing APCs provide additional B7 co-stimulation. We think this formal possibility is not critical because we also saw little difference in responder CD4 Tcell proliferation in wild-type and CD28ÿ/ÿ hosts if we used antigen-pulsed DCs instead of systemic antigen (data not shown). Finally, it should be noted that endogenous T cell competitors are relatively defective in CD28ÿ/ÿ hosts. However, we do not believe this to be an essential difference either since the endogenous ovalbuminspecific fraction is relatively minor compared with the adoptively transferred population of DO11.10 T cells. Thus, we think it is most likely that the difference in the effects of regulatory CD25+CD4 T cells on clonal expansion between the two systems is due to a difference in the number and types of participating APCs.
We found it interesting to see IL-4 production by DO11.10 T cells in CD28ÿ/ÿhosts following immunization with ovalbumin protein alone and even with CFA. We have not seen differentiation by DO11.10 T cells into T h 2 cells in the adoptive transfer system using wild-type recipients in the past despite multiple efforts to do so using a variety of adjuvants, including extracts of parasitic worms and testing a range of protein and peptide antigen doses (data not shown). Interestingly, we saw differentiation of DO11.10 into IL-4-producing cells in CD28ÿ/ÿ hosts only with protein, but not peptide antigen, even among the most highly divided cells. The reason for the difference is not clear at this time, although obviously the half-life of the peptide antigen and its distribution among various APCs is different from the protein. It has been hypothesized that T h 2 differentiation is the preferred pathway in the absence of any stimulation of pathogen-associated molecular pattern receptors (38) , although clearly antigen stimulation alone is not sufficient. Our results suggest that regulatory CD25+CD4 T cells are especially potent in suppressing T h 2 differentiation in vivo. However, CD28ÿ/ÿ hosts were also able to support T h 1 differentiation of DO11.10 cells when antigen was mixed with adjuvants, such as LPS and cholera toxin (data not shown), and co-transfer of CD25+CD4 T cells was able to suppress T h 1 differentiation. In fact, the ability of CD25+CD4 T cells to suppress CD4 T cell responses in the presence of LPS is somewhat surprizing since it was shown that soluble factors, which include IL-6, produced by DCs following LPS stimulation, abrogate suppressive abilities of CD25+CD4 T cells in vitro (39) . Clearly, a full mechanistic understanding of how CD25+CD4 T cells work can only result from a combination of in vitro and in vivo studies. 
